Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The company is focused on the development of novel treatments for RNA viruses
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Subscribe To Our Newsletter & Stay Updated
